Search Results - "Synnott, Patricia G."

The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals by Synnott, Patricia G., Voehler, Dominic, Enright, Daniel E., Kowal, Stacey, Ollendorf, Daniel A.

“…Background Efforts to understand how treatments affect patients and society have broadened the criteria that health technology assessment (HTA) organizations…”
Get full text

The impact of external reference pricing on pharmaceutical costs and market dynamics by Voehler, Dominic, Koethe, Benjamin C., Synnott, Patricia G., Ollendorf, Daniel A.

“…•Growth in the cost of prescription drugs has generated interest in external reference pricing (ERP).•Use of ERP for price negotiation is widespread…”
Get full text

Bridging the gap: aligning economic research with disease burden by Do, Lauren A, Synnott, Patricia G, Ma, Siyu, Ollendorf, Daniel A

“…IntroductionCost-effectiveness analysis (CEA) is critical for identifying high-value interventions that address significant unmet need. This study examines…”
Get full text

Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the “Optimal” Oral Anticoagulant for Atrial Fibrillation by Cameron, Christopher G., PhD, Synnott, Patricia G., MS, MALD, Pearson, Steven D., MD, MSc, Dubois, Robert W., MD, PhD, Ciarametaro, Michael, MBA, Ollendorf, Daniel A., PhD

“…Abstract Objectives To investigate heterogeneity of treatment effect (HTE) for anticoagulants in atrial fibrillation across subgroups defined by 1) clinical…”
Get full text

Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease by Zimmermann, Marita, Lubinga, Solomon J., Banken, Reiner, Rind, David, Cramer, Geri, Synnott, Patricia G., Chapman, Richard H., Khan, Sonya, Carlson, Josh

“…The gene therapy voretigene neparvovec (VN) is the first Food and Drug Administration–approved treatment for vision loss owing to the ultra-rare RPE65-mediated…”
Get full text

Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks by Riley, Abigail G., Voehler, Dominic, Mitrovich, Rachel, Carias, Cristina, Ollendorf, Daniel A., Nelson, Katherine L., Synnott, Patricia G., Eiden, Amanda L.

“…Economic evaluations of vaccination may not fully account for nonhealth patient impacts on families, communities, and society (ie, broader value elements)…”
Get full text

The effectiveness and value of aducanumab for Alzheimer’s disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum by Synnott, Patricia G, Whittington, Melanie D, Lin, Grace A, Rind, David M, Pearson, Steven D

Get full text

Developing Criteria for Health Economic Quality Evaluation Tool by Kim, David D., Do, Lauren A., Synnott, Patricia G., Lavelle, Tara A., Prosser, Lisa A., Wong, John B., Neumann, Peter J.

“…Because existing publication guidelines and checklists have limitations when used to assess the quality of cost-effectiveness analysis, we developed a novel…”
Get full text

Modeling the Population Equity of Alzheimer Disease Treatments in the US by Synnott, Patricia G, Majda, Thomas, Lin, Pei-Jung, Ollendorf, Daniel A, Zhu, Yingying, Kowal, Stacey

“…The arrival of new medications for Alzheimer disease (AD) has prompted efforts to measure their value using conventional cost-effectiveness analyses; however,…”
Get full text

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States by Carlson, Josh J, Guzauskas, Gregory F, Chapman, Richard H, Synnott, Patricia G, Liu, Shanshan, Russo, Elizabeth T, Pearson, Steven D, Brouwer, Elizabeth D, Ollendorf, Daniel A

“…New 3-drug regimens have been developed and approved to treat multiple myeloma (MM). The absence of direct comparative data and the high cost of treatment…”
Get full text

The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia by Lancaster, Victoria, Richardson, Marina, Beaudoin, Francesca L, Synnott, Patricia G, Rind, David M, Herce-Hagiwara, Belén, Campbell, Jon D, Pearson, Steven D

Get more information

Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model by Kumar, Varun M., Agboola, Foluso, Synnott, Patricia G., Segel, Celia, Webb, Maggie, Ollendorf, Daniel A., Banken, Reiner, Chapman, Richard H.

“…Opioid abuse is a significant public health problem in the United States. We evaluate the clinical effectiveness and economic impact of abuse-deterrent…”
Get full text

Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis by Whittington, Melanie D, McQueen, R Brett, Ollendorf, Daniel A, Chapman, Richard H, Kumar, Varun M, Synnott, Patricia G, Agboola, Foluso, Campbell, Jonathan D

“…Rheumatoid arthritis is associated with a societal burden greater than $39 billion annually. Novel treatments, known as targeted immune modulators (TIMs), are…”
Get full text

Estimating Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s disease in the United States by Spargo, Drew, Zur, Richard, Lin, Pei‐Jung, Synnott, Patricia G, Klein, Eric, Hartry, Ann

“…Background In the United States (US), early Alzheimer’s disease (AD) is underdiagnosed due to numerous factors such as inadequate lab testing, lack of symptom…”
Get full text

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council by Synnott, Patricia G., Bloudek, Lisa M., Sharaf, Ravi, Carlson, Josh J., Pearson, Steven D.

Get full text

The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council by Synnott, Patricia G., McQueen, R. Brett, Ollendorf, Daniel A., Campbell, Jonathan D., Pearson, Steven D.

Get full text

The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council by Lancaster, Victoria, Richardson, Marina, Beaudoin, Francesca L, Synnott, Patricia G, Rind, David M, Herce-Hagiwara, Belén, Campbell, Jon D, Pearson, Steven D

Get full text

The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council by Tice, Jeffrey A., Campbell, Jonathan D., Synnott, Patricia G., Walsh, Judith M. E., Kumar, Varun M., Whittington, Melanie, Adair, Ellie, Rind, David, Pearson, Steven D.

Get full text

Author Reply by Zimmermann, Marita, Lubinga, Solomon J., Banken, Reiner, Rind, David, Cramer, Geri, Synnott, Patricia G., Chapman, Richard H., Khan, Sonya, Carlson, Josh

Get full text

Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration–Approved Gene Therapy and Implications for Future One-Time Therapies/Author Reply by Buessing, Marric, O'Connell, Thomas, Johnson, Scott, Pitluck, Sarah, Ciulla, Thomas A, Zimmermann, Marita, Lubinga, Solomon J, Banken, Reiner, Rind, David, Cramer, Geri, Synnott, Patricia G, Chapman, Richard H, Khan, Sonya, Carlson, Josh

Get full text